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Abstract 
Background: Foam sclerotherapy is a potential treatment for lower limb venous 
disease.   
Methods: A systematic review, with no restriction on study design, to assess the 
safety and efficacy of foam sclerotherapy. 
Results: 69 studies were included. For serious adverse events including pulmonary 
embolism and deep vein thrombosis, the median event rates were less than 1%.  
Median rate for visual disturbance was 1.4%. Median rates for some other adverse 
events were more common, including headache (4.2%), thrombophlebitis (4.7%), 
matting/skin staining/pigmentation (17.8%) and pain at the site of injection (25.6%).  
Median rate for complete occlusion of treated veins was 87.0% and for recurrence or 
development of new veins was 8.1%. Evidence from meta-analysis for complete 
occlusion suggests that foam sclerotherapy is associated with a lower rate compared 
with surgery (RR 0.86, 95% CI 0.67 to 1.10) and a higher rate compared with liquid 
sclerotherapy (RR 1.39, 95% CI 0.91 to 2.11). However, there was substantial 
heterogeneity across the studies in the meta-analysis.   
Conclusion: Serious adverse events were rare. There is insufficient evidence to reliably 
compare the effectiveness of foam sclerotherapy with other minimally invasive therapies or 
surgery.   Evidence from high quality randomised controlled trials is required  
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Introduction 
Venous disease of the lower limbs includes varicose veins, reticular veins, 
telangiectasiae and all of the skin changes of advanced venous dysfunction including 
oedema, eczema, pigmentation, lipodermatosclerosis and ulceration.  Current 
treatment options include compression hosiery, endovenous laser ablation treatment, 
radiofrequency ablation, open surgery (ligation, stripping and phlebectomies), and 
subfascial endoscopic perforator surgery alone or in combination, and sclerotherapy, 
which is mostly carried out as an outpatient procedure with no anaesthesia required. 
Sclerotherapy techniques in current use are liquid and foam sclerotherapy.  Liquid 
sclerotherapy involves the injection of sclerosing liquid into affected veins leading to 
an inflammatory reaction and consequent venous occlusion1.  Foam sclerotherapy is a 
modification of liquid sclerotherapy but instead of injecting liquid, the liquid is 
transformed into foam by forcibly mixing it with air2-4 or other type of gas such as 
oxygen or carbon dioxide.   
Foam sclerotherapy may be a potential treatment for all categories of venous 
disease, although currently, its use in the UK is ‘off licence’. Anaphylaxis, vascular 
events such as cerebrovascular accident, myocardial infarction, and thromboembolism 
are serious potential complications of foam sclerotherapy.  Other adverse events 
associated with foam sclerotherapy include transient visual disturbance, cutaneous 
necrosis or ulceration, and local effects such as ‘minor’ vein thrombosis, 
thrombophlebitis, local neurological injury, and skin pigmentation. 
The objective of this study was to systematically review the safety and 
efficacy of foam sclerotherapy for treating venous disease of the lower limbs. 
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Methods 
Search strategy 
Extensive electronic searches were conducted to identify reports of published, 
unpublished and ongoing studies and included abstracts from conference proceedings 
and other grey literature sources.  There were no restrictions in terms of language or 
publication year. The search strategies were designed to be highly sensitive, including 
both appropriate subject heading and text word terms. Full details of the search 
strategies used are available from the authors. Databases searched included Medline 
(1966 – May Week 2 2006), Embase (1980 – Week 20 2006), Medline in-process 
(23rd May 2006), Biosis (1969 – 19th May 2006), Science Citation Index (1981 – 20th 
May 2006), ISI proceedings (1990-23rd June 2006), Cochrane Controlled Trials 
Register (The Cochrane Library, Issue 2, 2006), Conference Papers Index (2000- June 
2006), Cochrane Database of Systematic Reviews (The Cochrane Library, Issue 2, 
2006), Database of Abstracts of Reviews of Effectiveness (April 2006), HTA 
Database (April 2006), National Research Register (Issue 2, 2006), Clinical Trials 
(June 2006) and Current Controlled Trials (June 2006). Electronic and hand searching 
of conference proceedings of phlebology and vascular organisations was undertaken.  
The table of contents of two phlebology journals (Phlebologie (1970-2005) and 
Australasian Journal of Phlebology (1999-2004)), not consistently indexed in the 
major databases, were also checked.  Relevant professional and commercial websites 
were searched and the reference lists of all included studies were scanned.  
 
Inclusion and exclusion criteria 
Randomised controlled trials (RCTs), non-randomised comparative studies (NRCS), 
case series, case reports, and prospective population-based registry reports of foam 
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sclerotherapy for treating venous disease of the lower limbs in adults aged 16 years 
and above were sought.  Treatment of cutaneous venous malformations was excluded.  
Safety outcomes were classified into serious adverse events and adverse 
events. Serious adverse events assessed included anaphylaxis, arterial events, venous 
thromboembolism, cutaneous necrosis and ulceration, and other serious adverse 
events such as epileptic fits; adverse events included visual disturbance, central 
nervous system disturbance (such as confusion, migraine and other type of headache), 
other systemic symptoms (such as coughing, chest tightness, and vasovagal), local 
effects (such as ‘minor’ vein thrombosis, thrombophlebitis, matting/skin 
staining/pigmentation, local neurological injury, pain provoked on injection and pain 
persisting at the sclerosed area), and other adverse events (such as allergic reaction 
(local or systemic) and haematoma).   
Efficacy outcomes assessed included complete occlusion of treated veins, 
healing of venous ulceration, recurrence of varicose veins and development of new 
veins, quality of life (such as time to return to normal activity, patient satisfaction, 
symptom relief, and change of venous disease severity measured by Venous Clinical 
Severity Score5) and procedure time. For quality of life and procedure time only 
outcomes from comparative studies were considered.   
Complete occlusion of treated veins included outcomes reported as complete 
venous occlusion, elimination of reflux (if complete venous occlusion was not 
reported) and success rate (if complete venous occlusion or elimination of reflux were 
not reported).  Veins remaining patent, partial occlusion, partial occlusion with 
minimal retrograde flow, and having residual segments not occluded were classed as 
treatment failure.   
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Where data were available, immediate (≤24 hours), short-term (≤30 days) and 
longer-term (>30 days) adverse events, and short-term (≤30 days) and longer-term 
(>30 days) efficacy were assessed.  Where data on longer-term outcomes were 
reported for several time points later than 30 days then the data for the longest follow-
up period was used. 
 
Quality assessment  
Two reviewers independently assessed the quality of the included English language 
full text studies.  Any disagreements were resolved by consensus or arbitration by a 
third party. 
 
Data analysis 
Median event rates (and ranges) were tabulated by study design.  Studies reporting the 
number of limbs or veins but not patient level data (22 studies) were not included 
when calculating the medians and ranges but were reported separately.  
A random effects meta-analysis of RCTs was conducted to compare foam 
versus liquid sclerotherapy and foam sclerotherapy versus surgery where two or more 
studies were available. Within-patient studies were not considered. Review Manager 
(RevMan 4.2.8) software was used.  We assessed heterogeneity between studies using 
the I-squared statistic.   
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Results 
Number, type and quality of included studies 
69 studies6-73 (in 104 reports) were included (Table 1, available on BJS website). 28 
of the included studies were English full text studies6-31 (eight RCTs6-12, one 
registry13, one non-randomised comparative study14, 14 case series15-27 and four case 
reports28-31). 24 studies were English conference abstracts32-56 (two RCTs32,33, five 
non-randomised comparative studies34-38 and 17 case series39-56). 16 studies were non-
English full text studies or conference abstracts57-72 (two non-randomised comparative 
studies57,58, 13 case series59-71 and one case report72). One study was unpublished73. 
The follow-up time of eight studies was over three years7,17,18,25,37,38,45,53. The sample 
size in 36 studies was over 1006,7,10,12,13,15-19,21,22,25,32,34,35,38,39,46,49,50,52-55,58-60,62-67,70,71. 
Figure 1 shows the screening process. 
In the included studies over 9000 patients were treated with foam 
sclerotherapy. The most common indications for foam sclerotherapy were truncal vein 
(great and/or small saphenous vein) incompetence or varicosities.  The most 
frequently used sclerosing agent was polidocanol, with a strength ranging from 0.25 
to 3%.  The most commonly used foam-producing technique was the Tessari 
technique, in which two syringes are connected by a three-way valve and fluid 
sclerosant is forcibly mixed with air and frothed into foam by a pumping action.  Most 
studies used ultrasound guidance for identifying treated veins and monitoring foam 
injection and/or foam flow.  Table 2 (available on BJS website) shows the 
demographic details and indication for treatment for the included English language 
full text studies and studies in English language conference abstracts (these data were 
not extracted for non-English language studies).   
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The methodological quality of the included RCTs was generally low.  The 
treatment allocation was adequately concealed in only one of seven RCTs7 and three 
studies conducted an intention to treat analysis7,9,11.  The methodological quality of 
conference abstracts and non-English language studies was not assessed.  The sample 
sizes of most studies were more than 100. Length of follow-up in most studies, 
irrespective of study design, was more than 30 days. No studies reported methods of 
follow-up. The completeness of follow-up ranged from 70 to 100%.  
 
Safety 
Serious adverse events 
Table 3 summarises the serious adverse events associated with foam sclerotherapy.  In 
the included studies serious adverse events associated with foam sclerotherapy 
occurred in 0 to 5.7% of treatments.  Studies including anaphylaxis13,21,26 or intra-
arterial injections13,66 as outcomes reported that no events occurred.  Although no 
arterial events occurred in a single large case series21 involving 808 patients, they did 
occur, at a median rate of 2.1% (range 1.4 to 2.8) in two conference abstracts39,43 
involving 253 patients.  The events were reported as stroke (n=1, for details see 
below)43 and transient ‘embolic’ events (no details provided)39. Five English language 
case series16-18,20,23 involving 1316 patients reported one patient suffering a pulmonary 
embolism.  Deep vein thrombosis occurred at a rate of 0.02% in the French registry13 
and at a median rate of 0.6% (range 0 to 5.7%) in 25 other studies8,10,12,16-
24,26,35,40,42,46,49,55,60,63,65,71.  Cutaneous necrosis occurred at a median rate of 1.3% 
(range 0.3 to 2.6%) in four English language case series16,22-24 involving 781 patients 
and at a median rate of 0% (range 0 to 0.2%) in five studies available as conference 
abstracts50,56 or non-English language studies57,61,71 and involving 766 patients.  No 
 
8
cutaneous ulceration occurred in three English language studies8,10,26 reporting on this 
outcome, although one small non-English language study69 involving 28 patients 
reported an event.   
The stroke reported in the case series43 was further detailed in a case report44.  
This occurred in a 61 year old man who underwent foam sclerotherapy to the great 
saphenous vein.  The patient was reported as having fully recovered. A carotid duplex 
scan, performed immediately, showed normal arteries with rapidly moving echogenic 
particles within the left carotid lumen. This was similar to the duplex appearance of 
foam in the great saphenous vein. A transoesophageal echocardiogram revealed an 18 
mm Patent Foramen Ovale (PFO) with an associated atrial septal aneurysm. A right-
to-left shunt was demonstrated with a colour flow duplex scan and the bubble test on 
the transoesophageal echocardiogram.  
An unpublished case report73 recorded one case of myocardial infarction 
occurring 30 minutes following injection. This occurred in a 70 year old, otherwise 
healthy woman who underwent foam sclerotherapy to the incompetent left great 
saphenous vein.  An echocardiogram (type of echocardiogram not specified) showed 
no right-to-left shunt.  The patient had reported scotomas following a previous 
treatment.   
A grand mal epileptic fit was reported in an unpublished case report73. Forty 
minutes after injection, a 70 year old man experienced scintillating scotomas, 
followed by confusion, stupor, and then a grand mal seizure.  Subsequent 
investigations found no evidence of myocardial infarction, cardiovascular accident, 
septal defects (right-to-left shunt), deep vein thrombosis, pulmonary embolism or 
sepsis.  It was unclear whether he had a history of epilepsy. 
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Adverse events 
Table 4 summarises the adverse events associated with foam sclerotherapy.  
Visual disturbance occurred at rate of 0.3% in the French registry13 and a 
median rate of 1.4% (range 0 to 5.9%) in 14 other studies10,16-23,27,35,58,66. There were 
no reports of visual disturbance lasting longer than two hours or long-term or 
permanent visual impairment.  Transient confusion occurred at a median rate of 0.5% 
(range 0 to 1.2%)20,22,23.  Headache occurred at rate of 0% in the French registry and a 
median rate of 4.2% in four other studies12,13,16,35. Other systemic symptoms, 
including coughing, chest tightness/heaviness, panic attack and malaise, and 
vasovagal events ranged from 0 to 2.8%13,16,17,19,22,24.  The French registry13 reported a 
rate of 0.2% for coughing and vasovagal events. 
‘Minor’ vein thrombosis occurred at a rate of 17.6% (9/51) in an English 
language RCT10, 0.1% in the French registry13, and a median rate of 1.2% (range 0 to 
4.2%) in seven other studies9,13,21,23,42,59,71. Thrombophlebitis occurred at a rate of 
45.8% (11/24) in a conference abstract42, 0.05% in the French registry13, and a median 
rate of 4.7% (range 0 to 25.0%) in 19 other studies8-10,17,20-23,27,35,40,51,52,59,64-66,69,71.  
Across studies, long-term (>30 days) matting/skin staining/pigmentation 
occurred at a median rate of 17.8% (range 0 to 66.7%). The median (range) rate was 
31.6% (7.8 to 55.1%) in four English language RCTs8,10,12 involving 517 patients, 
2.3% (0 to 19.8%) in five English language case series17,21-23,26 involving 759 patients, 
and 19.2% (in seven studies available as conference abstracts34,42,51,52,56 or non-
English language studies57,66 involving 484 patients.  
The occurrence of local neurological injury was less than 1% across all 
studies8,13,16-17,21,23,26.  Pain provoked by injection or persisting in the limbs varied 
across studies12,26,34,35,48,59,63 with a median rate of 25.6% (range 0.6 to 41.0%).  Other 
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adverse events reported included allergic reaction, haematoma, extravasation, and 
lower back pain. Haematoma occurred at a rate of 11.2% (29/259) in an English 
language RCT12 and the rates in seven other studies8,9,12,19,23,58,63 reporting other 
adverse events ranged from 0% to 6.2%.  
 
Comparative studies 
In the comparative studies, the relative risks associated with foam sclerotherapy 
compared with other treatments for most adverse events did not reach statistical 
significance.   However, in the French registry13 the risk of visual disturbance was 
significantly higher for the foam compared with the liquid sclerotherapy group 
(relative risk 16.1; 95% CI 2.2-120.6).  
In a meta-analysis of RCTs, the relative risk (RR) of two studies8,12 comparing 
foam with surgery, involving stripping, for the outcome of skin pigmentation, was not  
significantly different (RR 2.02, 95% CI 0.42 to 9.86) (Fig. 2). There was substantial 
heterogeneity between studies. 
 
Efficacy 
The follow-up period of the majority of studies reporting efficacy was less than three 
years.  Table 5 summarises the efficacy outcomes. 
 
Complete occlusion of treated veins and healing of venous ulcers 
The median rate of venous occlusion was 84.4% (range 67.4 to 93.8%) in the English 
language RCTs7-9,12 and 84.4% (60.0 to 98.2%) in the English language case 
series19,20,25,26, with a median rate of 87.0% (range 60.0 to 98.2%) across all studies7-
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9,12,14,19,20,25,26,32,35,38,40,48,50,53,54,59,63,64,66,70,71. The median rate of ulcer healing was 
80.5% (range 75.4 to 100%)16-18,33.   
In a meta-analysis of RCTs, the RR of three studies7,9,32 comparing foam with 
liquid sclerotherapy for the outcome of complete occlusion of treated veins tended to 
favour foam sclerotherapy (RR 1.39, 95% CI 0.91 to 2.11) (Fig. 3), while the RR in 
two studies8,12 comparing foam sclerotherapy with surgery involving stripping tended 
to favour surgery (RR 0.86, 95% CI 0.67 to 1.10) (Fig. 3).  However neither result 
was statistically significant and both meta-analyses demonstrated high heterogeneity 
across studies. 
 
Recurrence of venous disease and development of new veins 
Across studies7,9,14,17,25,32,48,51,54,59,63, the median rate of recurrence or development of 
new veins was 8.1% (range 10.1 to 27.8%). The highest rate was 51.2% which was 
reported in an RCT with a ten year follow-up7.   
In comparative studies, the risk of recurrence or development of new veins 
following foam sclerotherapy was not significantly different to that of comparator 
treatments9,14, other than in the RCT7 with the ten-year follow-up.  In this study the 
risk of developing new veins was significantly higher for foam sclerotherapy 
compared with surgery (ligation only: RR 1.4, 95% CI 1.02 to 1.8; ligation combined 
with liquid sclerotherapy: RR 1.4, 95% CI 1.1 to 1.9). 
 
Quality of life, disappearance of varicosities and changes of disease severity 
One RCT12 involving 272 patients reported that following foam sclerotherapy, 
patients required a median of two days to return to normal activity, significantly less 
than the 13 days following surgery.  Compared with liquid sclerotherapy or surgery, 
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there were no statistically significant differences in patient satisfaction6,10,38, 
disappearance of varicosities10,11 and change of disease severity as measured by the 
Venous Clinical Severity Score8. The follow-up of the above studies ranged from one 
month to one year. 
 
Procedure time and surgeon experience 
Only one study8 reported data on operation time (foam sclerotherapy plus ligation was 
45 minutes versus 85 minutes for ligation plus stripping plus avulsion).  The foam 
sclerotherapy was combined with sapheno-femoral junction ligation.  Few studies 
reported surgeon experience. 
 
On-going studies 
Three ongoing comparative studies63,74 (J Earnshaw, consultant Surgeon, 
Gloucestershire Royal Hospital) and two case series (K Darvall, Birmingham 
Heartlands Hospital; G Geroulakas, Ealing Hospital NHS Trust) were also identified. 
One RCT74 with 450 patients and two-year follow-up comparing foam sclerotherapy 
with surgery is currently in progress in the Netherlands. Another RCT63 with 158 
patients and about two-year follow-up comparing 3% and 1% polidocanol foam is 
currently in progress in France.  The sample sizes of the other three studies are all less 
than 200. The five ongoing studies, all with lengths of follow-up of less than three 
years, are due to be completed by 2009.  
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Discussion 
Concerning safety, serious adverse events including arterial events, pulmonary 
embolism, deep vein thrombosis, cutaneous necrosis and ulceration were statistically 
rare. The most common adverse events associated with foam sclerotherapy were 
thrombophlebitis, matting/skin staining/pigmentation, and pain provoked at injection 
or pain persisting at the sclerosed area.  Few studies reported that the risk of adverse 
events associated with foam sclerotherapy was significantly different to that of liquid 
sclerotherapy or open surgery. Generally, the comparative studies were too small to 
reliably detect differences in statistically rare adverse events at the level of the 
reported rates.  
Categorising the safety outcomes was problematic.  One reason for this is that 
the terminology for some outcomes was not used consistently across the included 
studies, for example ‘minor’ vein thrombosis was reported variously as microthrombi 
or sclerothrombus at superficial vein, and thrombophlebitis was reported as cutaneous 
inflammation or varicophlebitis.  Also, some authors might argue that 
thrombophlebitis should not be considered as an adverse event as it is part of the 
sclerosing effects.   It would also be argued that cutaneous necrosis or ulceration 
would be more appropriately grouped under adverse events rather than serious 
adverse events. 
Some adverse events, such as stroke, myocardial infarction, other arterial 
events, visual disturbance, and headache, may be more likely in people with a PFO.  
The prevalence of PFO has been reported as around 10%75. However only two 
included studies (both case reports involving four patients in total) examined the 
existence of PFO44,73. When considering the occurrence of post-procedural events of 
low or very low frequency, the potential of chance occurrence (i.e. due to 
 
14
“background” incidence) due to pathogenic mechanisms unrelated to foam 
sclerotherapy treatment should not be discounted.  This is difficult to quantify, but 
overall, events such as stroke and myocardial infarction are relatively common in the 
general population.  As a whole, the reported associations with adverse events do not 
elucidate the underlying pathophysiological mechanisms, and some of the reported 
adverse events might not have been caused by the treatment.  However as these 
adverse events occurred within around 30 minutes of the procedure, a causal effect 
cannot be ruled out.  
Concerning efficacy, foam sclerotherapy appears to be an efficacious 
treatment both for main trunk and minor vein disease.  The results from the studies 
reporting the number of limbs or veins, but not patients, were similar to those of the 
studies reporting patient-level data. However, there was insufficient evidence to 
reliably compare the efficacy of foam versus surgery or other minimally invasive 
therapies such as compression hosiery, endovenous laser ablation treatment and 
radiofrequency ablation.  Only six RCTs6-9,12,32 reporting venous occlusion were 
identified, with a follow-up of mostly less than three years.   
 Concerning the foam sclerotherapy techniques, the strength of polidocanol 
and STS used ranged from 0.25 – 3%, with the foam dose increasing as the size of 
vein increased.  No studies compared polidocanol with STS.  Few studies treated 
‘minor’ vein related venous disease only or recurrent venous disease only. Despite an 
extensive review there were insufficient data to determine the optimal volume of 
foam, concentration, and foam-producing methods to minimise the risks associated 
with the procedure and maintain efficacy.   
The evolution of foam sclerotherapy technique to include physically 
resolvable gas may have improved its safety and efficacy.  Four studies12,40,42,48 used 
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oxygen and carbon dioxide based foam, one of which was an English language full 
text study12, but these limited data were insufficient to fully assess the impact of using 
oxygen and carbon dioxide based foam, and there were also limited data to assess the 
effects of adding low molecular weight heparin injections46, elevating legs prior to 
treatment or increasing the pressure at the sapheno-femoral junction. 
Foam sclerotherapy requires a certain level of skill and training, which may 
impact on the safety and efficacy of the procedure.  However only one prospective 
case series21 gave details of the clinical experience and skill of the practitioner and 
two RCTs in one report12 suggested surgeons’ lack of foam sclerotherapy experience 
for large veins may cause higher adverse event rates such as deep vein thrombosis, 
headache, ‘minor’ vein thrombosis and haemotoma.  
There are no established guidelines in the UK for foam sclerotherapy 
concerning indications for treatment, use of off-licence foam sclerosants, foam-
producing technique, type and strength of fluid sclerosant, and the experience required 
by the practitioner to undertake the procedure.   However, the Australian College of 
Phlebology has produced guidance for the use of foam sclerotherapy76 and the 
German Society of Phlebology has also issued guidance77 on the concentration and 
volume of foam for sclerotherapy, based on a consensus meeting of European experts 
on foam sclerotherapy in 200378. The upper limits for volume of foam injected are 
20ml and 8ml respectively. 
Foam sclerotherapy is conducted as an outpatient procedure, does not require 
general anaesthesia and compared with surgery results in an earlier return to normal 
activities.  However, for foam treatment several sessions may be required.   
In conclusion, the available data suggested that serious adverse events were 
rare.  Some other adverse events, including headache, ‘minor’ vein thrombosis, 
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matting/skin staining/pigmentation, and pain at the site of injection, were more 
common.  There is insufficient evidence to reliably compare the effectiveness of foam 
sclerotherapy with other minimally invasive therapies or surgery.  High quality RCTs of 
foam sclerotherapy compared with surgery and with alternative minimally invasive 
treatments, and with a follow-up period of at least three years, are required to 
determine the comparative efficacy of foam sclerotherapy and its optimal place in 
clinical practice.  
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Table 1 Characteristics of included studies for safety and efficacy of foam sclerotherapy for venous disease of 
the lower limbs 
Reference Country  Follow-up Sample size 
English language full text studies 
RCT, n=8     
*Alos 20066 Spain 1 year (a) 75 foam  
(b) 75 liquid  
Belcaro 20037 Italy 10 years (a) 150 foam  
(b) 148 liquid  
(c) 136 liquid (high dose) 
(d) 155 surgery (ligation) 
(e) 144 surgery (stab avulsion) 
(f) 154 surgery (ligation) + liquid (high dose) 
Bountouroglou 20068 UK 3 months (a) 30 foam+ surgery (ligation) 
(b) 30 surgery (ligatin + stripping + avulsion) 
Hamel-Desnos 20039 France 1 year (a) 45 foam  
(b) 43 liquid 
Kern 200410 Switzerland 2 months (a) 51 foam  
(b) 45 liquid (polidocanol) 
(c) 51 liquid (chromated glycerine) 
Rao 200511 US 3 months (a) 10 foam  
(b) 19 liquid   
(c) 15 liquid (high strength) 
†Wright 200612 Multi-centre 3 months Centre 1:  
(a) 259 foam (O2 or CO2 based) 
(b) 125 foam (air based) or liquid  
Centre 2: 
(a) 176 foam (O2 or CO2 based) 
(b) 94 surgery (ligation, stripping or avulsion)  
Registries, n=1    
Guex 200513 France 1 month (a) 6395 (sessions) foam  
(b) 5434 (sessions) liquid  
(c) 344 (sessions) foam + liquid  
Non-randomised comparative studies, n=1 
Yamaki 200414 Japan 1 year (a) 37 foam  
(b) 40 liquid 
Case series, n=14    
Barrett 200415 US 2 years 116 (limbs) 
Bergan 200616 US 6 weeks 290 
Cabrera 200417 Spain 6 months to over 4 years 116 
Cabrera 200118 Spain 415 patients 4 to 6y 
72 patients mean 2.5y 
752 
Cavezzi 200219 Italy 1 month 194 
Cavezzi 199920 Italy Mean 21 weeks 98 
Coleridge-Smith 200621 UK 6 months 808 
‡Frullini 200222 Italy 20 to 180 days 257 
Hamada 200623 Egypt 1 year 60 
Kakkos 200624 UK 3 weeks 38 
McDonagh 200225 US 2 to 6 years 162 
Padbury 200426 Australia 6 months 14 
Tessari 200127 Italy 1 month 77 
Case reports, n=4    
De Waard 200528 Netherlands 3 weeks 1 
Lloret 200629 Spain 2 years 1 
Van Neer 200430 Netherlands 6 weeks 1 
Weaver 200431 Netherlands 6 months 1 
English language conference abstracts 
RCT, n=2    
Martimbeau 200332 US 1 year (a) 100 foam  
(b) 100 liquid  
Rybak 200333 Poland Not stated (a) 20 foam  
(b) 20 liquid 
Non-randomised comparative studies, n=5 
Chung  200334 South Korea Not stated (a) 52 foam  
(b) 76 liquid  
Gobin 200335 France 3 months (a) foam  
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Reference Country  Follow-up Sample size 
(b) liquid  
Gonzalez 200336 Chilli 1 month (a) 10 foam  
(b) 10 foam + heparin 
Grondin 200337 Canada 5 years (a) (number not stated) foam 1 shot 
(b) (number not stated) foam 1-3 sessions 
(c) (number not stated) surgery 
(d) (number not stated) liquid 
Grondin 200338 Canada (a) 10 months 
(b) 10 years 
(a) 150 foam (O2 or CO2 based) 
(b) 150 liquid 
Case series, n=17    
Baker 200639 UK Not stated 181 
Bhowmick 200140 UK 3 months 35 (O2 or CO2 based foam) 
Cavezzi 200341 Italy 2 years Nearly 100 (limbs) 
Coleridge-Smith 200342 UK Not stated 24 
Forlee 200643,44 Ireland 0 to 24 months 89 
Frullini 200145 Italy 5 years 21 
Gonzalez 200546 Chilli 2 years 143 
Mackay 200247 Not stated 1 year 13 
McCollum 200148 UK 3 months 41 
Morrison 200349 US Not stated 100 
Nitechki 200550 Israel Mean 10 months 423 
Sadoun 200351 France 2 years 20 
Schadeck 200152 France Not stated 318 
Sierra 200253 Not reported 5 years 360 
Tessari 200454 Italy Not stated 532 
Vin 200555 France 1 year 280 (limbs) 
Weiss 200256 Not stated 6 months 60 
Non-English language full text studies or conference abstracts 
Non-randomised comparative studies, n=2 
Benigni 199957 France 75 days (a) 10 foam 
(b) 10 liquid 
Demagny 200258 France 6 months (a) 200 (veins) foam 
(b) 200 (venis) liquid 
Case series, n=13    
Breu 200459 Germany 1 to 3 years 342 
Creton 200560 Not stated Not stated 130 
Ferrarra 200561 France 3 months 50  
Frullini 200062 Italy Not stated 167 veins 
Hamel-Desnos 200563 France 2 years 158 
Lucchi 200364 Italy 6 months 114 
Milleret 200465 Unclear  1 month 764 
Schadeck 200466 France Mean 14.7 months 108 
Sica 200567 France 1 year 148 
Sica 200368 France 2 years 52 
Stucker 200569 German Not stated 28 
Uhl 200570 Not stated Not stated 140 
Wildenhues 200571 Not stated 2 years 213 
Case reports, n=1    
Benigni 200572 France Not stated 5 
Unpublished studies     
Case report, n=1    
Krizinger 200673 Not stated Not stated 3 
*The RCT is a within-patient study  
†The report consisted of two studies (RCTs) 
‡the report consisted of two studies (case series) 
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Table 2 Patient details, indication for foam sclerotherapy and technique used  
 English 
language full 
text studies 
(n=24)* 
English language 
conference abstracts 
(n=21)†  
Patients 3935 2921 
   
Sex   
Male 410 (10.4%) 408 (14.0%) 
Female 1558 (39.6%) 1067 (36.5%) 
Not recorded 1967 (50.0%) 1446 (49.5%) 
   
Age group   
≥ 16 years 2616 (66.5%) 1656 (56.7%) 
Not recorded 1319 (33.5%) 1265 (43.3%) 
   
Indication for foam sclerotherapy    
‘Major’ vein (SFJ/GSV, SPJ/SSV) incompetence and/or varicosities  2735 (69.5%) 2073 (71.0%) 
‘Minor’ vein venous disease‡  131 (3.3%) 312 (10.7%) 
Both major veins and minor veins 676 (17.2%) 0 
Recurrent venous disease after prevous treatment 0 373 (12.8) 
Venous ulcers 83 (2.1%) 20 (0.7%) 
Not recorded 310 (7.9%) 143 (4.9%) 
   
Foam sclerotherapy technique   
Used STS as sclerosing solutions 668 (17.0%) 714 (24.4%) 
Used POL as sclerosing solutions 1838 (46.7%) 1805 (61.8%) 
Used either STS or POL (not reported separately) 1369 (34.8%) 352 (12.1%) 
Used ethanolamine oleate 60 (1.5%) 0 
Not recorded 0 50 (1.7%) 
   
Tessari method for producing foam  1848 (50.0%) 1349 (46.2%) 
Monfreux method for producing foam 406 (10.3%) 0 
Other methods for producing foam 367 (9.3%) 150 (5.1%) 
Not recorded 1314 (33.4%) 1422 (48.7%) 
   
Used ultrasound guidance to identify treated veins, monitor foam injection 
or foam flow 
3935 (100%) 1558 (53.3%) 
Use of ultrasound guidance not recorded  1363 (46.7%) 
   
One treatment session required 676 (92.6%)¶ N/a§ 
≥ 2 treatment sessions required 54 (7.4%)¶ N/a§ 
SFJ, saphenofemoral junction; GSV, great saphenous vein; SFJ, saphenopopliteal junction; SSV, small saphenous 
vein; STS, sodium tetradecyl sulphate; POL, polidocanol 
*Another study by Barrett et al15 reported number of limbs (n 116) but not number of patients.  The French 
registry13 reported number of treatment sessions but not number of patients. The details of the study were not listed 
in the table as it was not possible to calculate the number of patients.  
†One non-randomised comparative study by Grondin37 did not report number of patients or limbs.  One case series 
by Cavezzi41 reported number of limbs (nearly 100) but not number of patients.  One case series by Vin55 reported 
number of limbs (280) but not number of patients.  The details of the study were not listed in the table. 
‡‘Minor’ venous disease includes reticular vein, telangiectasia, tributaries vein varicosities and perforator vein 
incompetence. 
¶Treatment sessions required were calculated based on patient-level data. The data given in the table are from 
seven studies6,12,14,21,29-31 that provided details of the number of treatment sessions. Another 11 studies8,15-
20,22,24,26,27 reported mean treatment sessions, with the means ranging from 1.1 to 3.6 sessions. One study22 reported 
smaller veins (reticular veins and telangiectasias) separately, with a mean of 5 treatment sessions. 
§ No studies provided details of the number of treatment sessions at patient-level. Four studies32,34,41,56 provided 
details of the mean of treatment sessions at patient-level. The means ranged from 1.1 sessions to 2.3 sessions. One 
study53 treated recurrent veins after surgery and reported a mean of 5 sessions. 
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Table 3         Summary of serious adverse events associated with foam sclerotherapy for venous disease*† 
 No.  of studies‡  n/N Median rate (%)  (range) 
Anaphylaxis 
        Registry 113 0/6395¶ 0 
        Case series (English language full text studies) 221,26 0/822 0 
Arterial events 
        Case series (English language full text studies) 121 0/808 0 
        Studies in conference abstracts and non-English language 239,43 6/253  2.1 (1.4, 2.8) 
Venous thromboembolism: pulmonary embolism 
        RCT (English language full text studies) 212 0/437 0 
        Case series (English languagefull text studies) 516-18,20,23 1/1316 0 (0, 0.3) 
        Case series (non-English language studies) 262,71 0/977 0 
Venous thromboembolism: deep vein thrombosis 
        RCT (English language full text studies) 48,10,12 11/517 0.4 (0, 5.1) 
        Registry (English language full text studies) 113 1/6395¶ 0.02 
        Case series (English language full text studies) 1116-24,26 11/2828 0.4 (0, 1.0) 
        Studies in conference abstracts and non-English language 10 35,40,42,46,49,55,60,63,65,71 16/2076 0.7 (0, 5.7) 
Cutaneous: necrosis 
        RCT (English language full text studies) 19 0/45 0 
        Registry (English language full text studies) 113 0/6395¶  0 
        Case series (English language full text studies) 416,22-24 8/781 1.3 (0.3, 2.6) 
        Studies in conference abstracts and non-English language 550,56,57,61,71 1/766 0 (0, 0.2) 
Cutaneous: ulceration    
        RCT (English language full text studies) 28,10 0/80 0 
        Case series (English language full text studies) 126 0/14 0 
        Studies in conference abstracts and non-English language 169 1/28 3.6 
Other serious adverse events: intra-arterial injection    
        Registry 113 0/6395¶  0 
        Studies in conference abstracts and non-English language 166 0/108 0 
*Results from case reports were not in the table. Their results were: one case each of myocardial infarction and 
grand mal epileptic fit were reported by Kritizinger73
†The RCT by Alos et al6 is a within-patient study, therefore was not listed in the table. A non-English language 
study by Frullini & Cavezzi62, n 167 veins, did not report results at the patient level either, hence was not listed in 
the table.  
‡The report by Wright et al12 consisted of two studies (RCTs); the report by Frullini & Cavezzi22 consisted of two 
studies (case series). 
¶Guex 200513: adverse events were presented by number of treatment sessions rather than by number of patients.  
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Table 4        Summary of adverse events associated with foam sclerotherapy for venous disease*† 
 No.  of studies‡  n/N Median rate (%)  (range) 
Visual disturbance    
        RCT (English language studies) 110 3/51 5.9 
        Registry 113 19/6395¶ 0.3 
        Case series (English language studies) 1016-23,27 36/2848 1.1 (0, 2.6) 
        Studies in conference abstracts and non-English language      335,58,66 7/591 1.5 (0.9, 2.0) 
Central nervous system disturbance: transient confusion 
        Case series (English language studies) 420,22,23 4/611 0.5 (0, 1.2) 
Central nervous system disturbance: headache 
        RCT (English language studies) 212 55/437 14.2 (5.4, 23.0) 
        Registry 113 0/6395¶  0 
        Case series (English language studies) 116 2/290 0.7 
        Studies in conference abstracts and non-English language      135 7/229 3.1 
Other systemic symptoms: coughing, chest tightness/heaviness, panic attack and malaise, and vasovagal 
        Registry  113 10/6395¶  0.2 
        Case series (English language studies) 616,17,19,22,24 12/1091 0.5 (0, 2.8) 
Local effect: ‘minor’ vein thrombosis 
        RCT (English language studies) 29,10 9/96 8.8 (0, 17.6) 
        Registry 113 5/6395¶  0.1 
        Case series (English language studies) 221,23 11/868 1.5 (1.2, 1.7) 
        Studies in conference abstracts and non-English language 342,59,71 5/579 0.9 (0.6, 4.2) 
Local effect: thrombophlebitis 
        RCT (English language studies) 38-10 5/125 4.4 (0, 10.3) 
        Registry 113 3/6395¶  0.05 
        Case series (English language studies) 717,20-23,27 71/1612 3.3 (1.3, 10.3) 
        Studies in conference abstracts and non-English language     1035,40,42,51,52,59,64,66,69,71 81/1235 9.2 (0, 45.8) 
Local effect: matting/skin staining/pigmentation 
        RCT (English language studies) 48,10,12 226/517 31.6 (7.8, 55.1) 
        Case series (English language studies) 517,21-23,26 42/759 2.3 (0, 19.8) 
        Studies in conference abstracts and non-English language 734,42,51,52,56,57,66 74/484 19.2 (0, 66.7) 
Local effect: local neurological injury    
        RCT (English language studies) 18 0/29 0 
        Registry 113 1/6395¶  0.02 
        Case series (English language studies) 616-18,21,23,26 2/2040 0 (0, 0.7) 
Local effect: pain at the site of injection    
        RCT (English language studies) 212 150/437 35.7 (29.7, 41.0) 
        Case series (English language studies) 126 3/14 21.4  
        Studies in conference abstracts and non-English language    534,35,48,59,63 113/822 7.7 (0.6, 34.1) 
Others: local allergic reaction, haematoma, extravasations, lower back pain 
        RCT (English language studies) 48,9,12 41/511 4.2 (0, 11.2) 
        Case series (English language studies) 219,23 1/254 0.3 (0, 0.5) 
        Studies in conference abstracts and non-English language 258,63 1/412 0.3 (0, 0.6) 
*Results from case reports were not in the table. Their results were: six cases of visual disturbance and one case of 
chest heaviness were reported by Benigni & Ratinahirana72, Weaver31 and the unpublished case reports by 
Kritzinger73. 
†The RCT by Alos et al6 is a within-patient study, therefore was not listed in the table. Another four studies not 
reporting results at the patient level were not listed in the table either. Their results were: 
(1) Case series in English language full text study by Kakkos et al24, n=73 sessions/45 limbs, reported 8.2% 
thrombophlebitis and 6.6% matting/skin staining/pigmentation; 
(2) Case series in conference abstract by Forlee et al44 n=86 limbs, reported 1/86 limbs ‘minor’ vein thrombosis, 
11/86 limbs thrombophlebitis, and 33/86 limbs skin matting; 
(3) Case series in conference abstract by Vin55 n=280 limbs, reported 9/280 limbs thrombophlebitis;  
(4) Case series in non-English language study by Frullini & Cavezzi62, n=167 veins, 0.6% ‘minor’ vein 
thrombosis, 5/167 veins thrombophlebitis, 3.6% skin matting, and 0% allergic reaction; 
‡The report by Wright et al12 consisted of two studies (RCTs); the report by Frullini & Cavezzi22 consisted of two 
studies (case series). 
¶Guex 200513: adverse events were presented by number of treatment sessions rather than by number of patients.  
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Table 5         Summary of efficacy outcomes of foam sclerotherapy for venous disease* 
 No.  of studies† n/N Median rate (%) 
(range) 
Complete occlusion of treated veins 
     RCT (English language studies) 57-9,12 543/640 84.4 (67.4, 93.8) 
     Non-randomised comparative studies (English  language studies) 114 25/37 67.6 
     Case series (English language studies) 419,20,25,26 336/372 84.4 (60.0, 98.2) 
     Studies in conference abstracts and non-English language 1432,35,38,40,48,50,53,54,59,63,64,66,70,71 2488/2858 87.8 (74.1, 97.1) 
Healing of venous ulcers    
     Case series (English language studies) 316-18 181/216 84.5 (76.4, 100.0)
     Studies in conference abstracts and non-English language 133 15/20 75.0 
Recurrence or developed new veins    
     RCT (English language studies) 27,9 68/174 27.8 (4.4, 51.2) 
     Non-randomised comparative studies (English languages studies) 114 3/37 8.1 
Case series (English language studies) 2 17,25 7/291 3.1 (0.5, 5.7) 
     Studies in conference abstracts and non-English language 632,48,51,54,59,63 52/693 10.1 (1.0, 15.0) 
GSV, great saphenous vein; SSV, small saphenous vein 
*Another 18 studies not reporting results at the patient level were not listed in the table. Their results were: 
(1) Complete occlusion of treated veins: 
Case series in English language full text study: 
By Barrett et al.15, 68/99 limbs (vein diameter <10mm) (68.7%); 13/17 limbs (vein diameter ≥10mm) (75.5%); 
By Bergan et al.16, 259/328 limbs (79.0%); 
By Cabrera et al.18, 400/500 veins (GSV) (80.0%); 215/265 veins (recurrent) (81.1%); 
By Coleridge-Smith21, 318/365 veins (GSV) (87.6%); 116/141 veins (SSV) (82.3%); 
By Hamada et al.23, 88/112 veins (78.6%); 
Non-randomised comparative study in English language conference abstract: 
    By Grondin37, not reported number of patients or limbs,  
        foam group (1 session), GSV 85%, SSV 80%; foam group (1-3 sessions), GSV 88%, SSV 89%; 
        surgery group, GSV 85%, SSV 73%; liquid group, GSV 75%, SSV 82%; 
Case series in English language conference abstract: 
By Baker & Darke39, 196/229 limbs (85.6%); 
By Cavezzi41, 100/100 limbs (100%); 
By Coleridge-Smith42, 23/25 veins (GSV) (92.0%); 5/10 veins (SSV) (50.0%); 
By Forlee et al.43, 42/86 limbs (48.8%); 
By Gonzalez & Barahona-Cruz46, 91/106 veins (GSV) (85.8%); 62/69 veins (SSV) (89.9%); 
By Mackay47, 14/14 limbs (100%); 
By Schadeck52, 114/118 veins (saphenous/great collateral vein) (96.6%); 99/100 veins (recurrent) (99%); 92/100 
veins (telangiectatic) (92.0%); 
By Vin55, 207/280 limbs (73.9%);  
Non-randomised comparative study in non-English language: 
By Demagny58,  
GSV: foam group, 101/150 veins (67.3%); liquid group, 71/150 veins (47.3%); RR (95% CI), 1.4 (1.2, 1.7) 
SSV: foam group, 42/50 veins (84.0%); liquid group, 32/50 veins (64.0%); RR (95% CI), 1.3 (1.0, 1.7); 
Case series in non-English language: 
By Sica67, 93/107 veins (GSV) (86.9%); 39/41 veins (SSV) (90.2%); 
By Sica68, 79/97 veins (GSV) (81.0%); 25/29 veins (SSV) (87.0%); 
(2) Recurrence or developed new veins: 
Case series in English language full text study: 
By Barrett et al.15, 4/99 limbs (vein diameter <10mm) (4.0%); 1/17 limbs (vein diameter ≥10mm) (5.9%); 
Case series in English language conference abstract:   
By Coleridge-Smith42, 2/25 veins (GSV) (8.0%); 5/10 veins (SSV) (50.0%); 
By Forlee et al.43, 7/86 limbs (8.1%). 
Non-randomised comparative study in non-English language: 
By Demagny58,  
GSV: foam group, 16/150 veins (0.7%); liquid group, 33/150 veins (22.0%) 
SSV: foam group, 2/50 veins (4.0%); liquid group, 7/50 veins (14.0%); 
†The report by Wright et al12 consisted of two studies (RCTs). 
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Figure 1 Flow diagram for screening process 
Potentially relevant reports identified and 
screened for retrieval (n=1138) 
 
 
Reports retrieved for more detailed 
evaluation (n=291):  
Studies included (n=69, in 102 reports):  
10 RCTs, 1 registry,  
8 non-randomised comparative studies,  
44 case series and 6 case reports  
Excluded reports (n=189): 
Liquid sclerotherapy used (n=97),  
Results for foam sclerotherapy not presented 
separately from liquid sclerotherapy (n=3), 
No data presented (n=16), 
Excluded reports (n=847): not meeting 
inclusion criteria, e.g. liquid sclerotherapy used 
Other reasons, e.g. reviews (n=73) 
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Figure 2 Meta-analysis of foam sclerotherapy versus surgery involving stripping, for skin pigmentation 
 
 
 
 
Figure 3 Meta-analysis of foam versus liquid sclerotherapy, and foam sclerotherapy versus surgery, for complete 
occlusion of treated veins 
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